Variability of CYP2J2 expression in human fetal tissues

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 2, 2006, Pages 523-532

  Gaedigk, Andrea ^a   Baker, Darren W ^a   Totah, Rheem A ^b   Gaedigk, Roger ^a   Pearce, Robin E ^a   Vyhlidal, Carrie A ^a   Zeldin, Darryl C ^c   Leeder, J Steven ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2J2; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVITY; FETUS; FETUS (ANATOMY); GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; WESTERN BLOTTING;

ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; FETUS; GENOTYPE; HUMANS; LIVER; OXYGENASES; RNA SPLICING; RNA, MESSENGER;

EID: 33751191888     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.109215     Document Type: Article

References (26)

1. Cheesman MJ, Baer BR, Zheng Y, Gillam E, and Rettie AE (2003) Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group. Arch Biochem Biophys 416:17-24.
2. Enayetallah AE, French RA, Thibodeau MS, and Grant DF (2004) Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9 and 2J2 in human tissues. J Histochem Cytochem 52:447-454.
3. Gaedigk A, Gaedigk R, and Leeder JS (2005) CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? Biochem Biophys Res Commun 336:1241-1250.
4. Gu J, Su T, Chen Y, Zhang Q-Y, and Ding X (2000) Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol Appl Pharmacol 165:158-162.
5. Guryev O, Gilep A, Usanov S, and Estabrook R (2001) Interaction of apo-cytochrome b5 with cytochromes P4503A4 and P45017A: relevance of heme transfer reactions. Biochemistry 40:5018-5031.
6. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fuji T, Miyazaki H, Kamataki T, and Funae Y (2002) Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298-304.
7. Jiang J, Chen C-L, Card JW, Yang S, Chen J-X, Fu X-N, Ning Y-G, Xiao X, Zeldin DC, and Wang DW (2005) Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65:4707-4715.
8. King LM, Ma X, Srettabunjong S, Graves J, Bradburry JA, Li L, Spiecker M, Liao JK, Mohrenweiser H, and Zeldin DC (2002) Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 61:840-852.
9. Koch I, Weil R, Wolbold R, Brockmöller J, Hustert E, Burk O, Nuessler AC, Neuhaus P, Eichelbaum M, Zanger UM, et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114.
10. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
11. Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP, and Pearce RE (2005) Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther 314:626-635.
12. Lee SS, Jeong HE, Liu KH, Ryu JY, Moon T, Yoon CN, Oh SJ, Yun CH, and Shin JG (2005) Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics 15:105-113.
13. Le Quere V, Plee-Gauter E, Potin P, Madec S, and Salaun JP (2004) Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxides. J Lipid Res 45:1446-1458.
14. Marden NY and Murray M (2005) Characterization of a c-Jun-responsive module in the 5′-flank of the human CYP2J2 gene that regulates transactivation. Biochem J 391:631-640.
15. Matsumoto S, Hirama T, Matsubara T, Nagata K, and Yamazoe Y (2002) Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 30:1240-1245.
16. Mitsuda M and Iwasaki M (2006) Improvement in the expression of CYP2B6 by co-expression with molecular chaperones GroES/EL in Escherichia coli. Protein Expr Purif 46:401-405.
17. Nalla VK and Rogan PK (2005) Automated splicing mutation analysis by information theory. Hum Mutat 25:334-342.
18. Rogan PK, Faux BM, and Schneider TD (1998) Information analysis of human splice site mutations. Hum Mutat 12:153-171.
19. Rogan PK, Svojanovsky S, and Leeder JS (2003) Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics 13:207-218.
20. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
21. Smith K (1975) Porphyrins and Metalloporphyrins, Elsevier Science, Amsterdam.
22. + channels and p42/p44 MAPK pathway. Circ Res 95:506-514.
23. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Borgel J, Mugge A, Lindpaintner K, et al. (2004) Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110:2132-2136.
24. Wang H, Jiang Y, Liu Y, Lin C, Cheng G, Chen X, Hao B, Tan W, Lin D, and He F (2006) CYP2J2*7 single nucleotide polymorphism in a Chinese population. Clin Chim Acta 365:125-128.
25. Wu S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468.
26. Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, and Kroetz DL (2000) Increased CYP2J2 expression and epoxyeicosatrienoic acid formation in spontaneous hypertensive rat kidney. Mol Pharmacol 57:1011-1020.